Genmab — December 2015

[Fantomas]

Så ville man nok gøre det enten før eller efter, for ikke at risikere at det drukner i mængden under ASH

[Fantomas]

jeg har heller ikke kunne finde det, men MUFC siger at det sker.

[Mcjean]

Alt er muligt, men spændende især fordi det er søndag og jeg drikker normalt ikke om søndagen:-)

[Budweis]

har ikke lige set denne før - http://www.nxtbook.com/nxtbooks/customnews/ashnewsdaily2015_Sunday/

[Budweis]

Janssen har taget deres plads på p.3

[jkj]

Det er en and

[royal]

Og forsiden.

[Budweis]

JA!

[Budweis]

JanssenUS @JanssenUS
#ASH15 Press Program starts in 15 min: Check out GEN503 #myeloma and RESONATE-2 #CLL data!

[MUFC_Oberanven]

Tak Budweis

[Mcjean]

Ok så pressprogram and not presskonference, så er det nok hype og advertising

[Budweis]

lad se om de smider en pressemeddelse - det lugter af støj

[bassemanden]

er der et live link

[Budweis]

kan ikke finde noget

[royal]

Måske Jans forfar? http://uncyclopedia.wikia.com/wiki/File:Getafix.jpg

[Budweis]

http://www.janssen.com/ibrutinib-imbruvica-significantly-improved-progression-free-and-overall-survival-versus-chlorambucil

[Budweis]

press program

[Budweis]

http://www.janssen.com/daratumumab-darzalex-combined-standard-treatment-multiple-myeloma-produced-deep-and-durable

[Budweis]

Janssen Research & Development, LLC announced new data from the ongoing Phase 1/2 GEN503 investigational study showing the human CD38-directed monoclonal antibody daratumumab (DARZALEX), in combination with lenalidomide and dexamethasone, yielded an overall response rate (ORR) of 81 percent in relapsed or refractory multiple myeloma patients who had received a median of two prior therapies.

[Budweis]

After 18 months of treatment, investigators observed an overall survival (OS) rate of 90 percent, with 72 percent of patients experiencing progression-free survival (PFS).